First Gaucher type 3 neurological drug approved - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

First Gaucher type 3 neurological drug approved

  • By

  • Teraya Smith

  • November 18, 2026

  • 2 min

Share

  • 1

    The FDA approved venglustat (Infilbray) for neurological symptoms of type 3 Gaucher disease in adults and children weighing at least 15 kg.

  • 2

    Venglustat crosses the blood-brain barrier and inhibits glucosylceramide synthase, reducing glucosphingolipid accumulation.

  • 3

    Approval was supported by a 52-week randomized trial of 43 patients aged 12 years or older with stable systemic disease after enzyme replacement therapy.

  • 4

    At week 52, venglustat improved a combined neurological assessment compared with enzyme replacement therapy, but the FDA announcement provided no numerical effect estimates.

  • 5

    Reported adverse effects included gastrointestinal symptoms and mood changes; serious psychiatric risks included suicidal ideation and behavior.

Original Source(s)

Related Content